Welcome to our dedicated page for BOSTON SCIENTIFIC SEC filings (Ticker: BSX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BOSTON SCIENTIFIC's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BOSTON SCIENTIFIC's regulatory disclosures and financial reporting.
Boston Scientific Corp director Edward J. Ludwig purchased 5,000 shares of common stock on July 31, 2026 at an average price of $45.4799 per share. After this open-market or private transaction, he directly owns 30,359 shares. The trade was not reported under a Rule 10b5-1 plan.
Boston Scientific Corp executive Joseph Michael Fitzgerald, EVP & Group President, Cardiology, reported a discretionary acquisition of 64,198 shares of common stock on 2026-07-31 through a rebalance of his holdings under the company’s 401(k) Retirement Savings Plan at $46.73 per share. These shares are held indirectly via the 401(k), which now reflects that balance. Separate entries show 213,907 shares held directly and 5,234 shares held by his child, with a footnote stating he disclaims beneficial ownership of the child’s shares.
Boston Scientific Corporation reported strong results for the quarter ended June 30, 2026, with net sales of $5.442 billion, up 7.5 percent on a reported basis and 7.0 percent on an operational and organic basis versus a year earlier. GAAP net income attributable to common stockholders was $907 million, or $0.61 per diluted share, compared with $797 million, or $0.53 per share. Adjusted EPS was $0.86, up from $0.75 and above the company’s guidance range of $0.82 to $0.84.
MedSurg net sales were $1.818 billion, up 5.9 percent reported, while Cardiovascular reached $3.624 billion, up 8.3 percent. Regional growth was 6.2 percent in the U.S., 11.2 percent in Asia-Pacific and 22.4 percent in Latin America and Canada on a reported basis.
The company completed a $2 billion accelerated share repurchase program, buying approximately 40 million shares, and invested $1.5 billion for an approximately 34 percent stake in MiRus LLC with an exclusive option on its TAVR business. For 2026, it projects reported net sales growth of 5.5 to 6.5 percent and adjusted EPS of $3.28 to $3.32, with third-quarter adjusted EPS expected at $0.80 to $0.82.
Boston Scientific Corporation approved a new global restructuring program, the 2026 Restructuring Plan, on July 21, 2026. The plan is intended to drive sustained cost efficiencies and support growth by optimizing the supply chain, transferring certain production lines among facilities, and reshaping functional and organizational structures.
The program is expected to be initiated in 2026 and substantially completed by the end of 2029. Boston Scientific estimates total pre-tax charges of $700 million to $800 million, including $300 million to $350 million of transfer costs, $275 million to $300 million of termination benefits, and $125 million to $150 million of other costs such as consulting, contractual cancellations, program management, accelerated depreciation and fixed asset write-offs. Of the total charges, $600 million to $700 million are expected to result in future cash outlays.
The company expects the plan to reduce gross annual pre-tax expenses by approximately $500 million as benefits are realized, with a substantial portion of these savings to be reinvested in strategic growth initiatives. While new roles will be created in growth areas, the company does expect some headcount reductions as a result of the restructuring.
Boston Scientific EVP and CFO Jonathan Monson reported routine equity compensation activity involving restricted stock units. He exercised 2,087 restricted stock units into 2,087 shares of common stock and, in a related tax-withholding disposition, 1,010 shares were withheld at a price of $43.06 per share to cover tax obligations. After these transactions, he directly holds 39,063 shares of common stock and 6,263 restricted stock units, which each represent a commitment by the company to issue one share of common stock in the future, with shares to be issued in four equal annual installments beginning on July 1, 2026.
Boston Scientific Chairman, President & CEO Michael F. Mahoney reported a large charitable-style transfer of stock. He made a bona fide gift of 386,755 shares of Boston Scientific common stock on May 28, 2026 to The Michael F. Mahoney Term Irrevocable Trust - 2026, which is administered by an independent trustee.
After this transaction, Mahoney continues to hold 1,403,784 shares of Boston Scientific common stock directly. The gift is a non-market disposition with no sale proceeds reported, meaning it does not reflect open-market buying or selling activity in the stock.
Boston Scientific director Cheryl Pegus bought 1,770 shares of common stock in an open-market transaction. The purchase occurred at a weighted average price of about $56.49 per share, across multiple trades priced between $56.49 and $56.5009. After this transaction, she directly owns 1,770 shares.
BOSTON SCIENTIFIC CORP director Edward J. Ludwig made an open-market purchase of 3,580 shares of Common Stock at $56.68 per share. The transaction occurred on May 20, 2026 and increased his direct ownership to 25,359 shares following the trade.
Boston Scientific Corp director David C. Habiger reported buying additional company stock in two recent open-market transactions. He purchased 2,200 shares of Common Stock on May 19, 2026 at a weighted average price of $56.9451 per share, and 2,250 shares on May 20, 2026 at a weighted average price of $55.9195 per share. According to the filing, individual trades on each day occurred within narrow price ranges around these averages. Following these purchases, Habiger directly owns 13,878 Boston Scientific common shares.